Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.
Jiawen DengFangwen ZhouKiyan HeybatiSaif AliQi Kang ZuoWinston HouThanansayan DhivagaranHarikrishnaa Ba RamarajuOswin ChangChi Yi WongZachary SilverPublished in: Future virology (2021)
Aims: To evaluate the efficacy and safety of hydroxychloroquine/chloroquine, with or without azithromycin, in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in a random-effects meta-analysis. Primary outcomes included time to negative conversion of SARS-CoV-2 tests, length of stay, mortality, incidence of mechanical ventilation, time to normalization of body temperature, incidence of adverse events and incidence of QT prolongations. Results: Fifty-one studies (n = 61,221) were included. Hydroxychloroquine/chloroquine showed no efficacy in all primary efficacy outcomes, but was associated with increased odds of QT prolongations. Conclusion: Due to a lack of efficacy and increased odds of cardiac adverse events, hydroxychloroquine/chloroquine should not be used for treating hospitalized COVID-19 patients.
Keyphrases
- sars cov
- mechanical ventilation
- risk factors
- systematic review
- respiratory syndrome coronavirus
- plasmodium falciparum
- open label
- cardiovascular disease
- cardiovascular events
- left ventricular
- electronic health record
- machine learning
- drug induced
- skeletal muscle
- big data
- artificial intelligence
- atrial fibrillation
- deep learning
- insulin resistance
- glycemic control
- study protocol
- respiratory failure
- phase iii